Education
About Us
Working with TipRanks
Follow Us
BeiGene (ONC)
NASDAQ:ONC
Top Page
BeiGene
(NASDAQ:ONC)56Neutral
Positive Factors
Earnings
BeiGene reported a blowout quarter exceeding analyst and consensus expectations, with Brukinsa overtaking Calquence in the U.S. market.
Product Approval
Tevimbra received approval as a treatment for 1L esophageal squamous cell carcinoma in the U.S., providing a potential tailwind to future revenue guidance.
Revenue Guidance
The company provided total revenue guidance for 2025 in the range of $4.9-$5.3B, well ahead of analyst estimates of $4.6B.
Negative Factors
Expenses
Beigene’s R&D/SG&A expense rose by 10%/21% YoY, but the company’s loss from operations narrowed to US$568.2mn in 2024 from US$1,207.7mn in 2023.
BeiGene (ONC) vs. S&P 500 (SPY)
Market Cap
$29.41B
Dividend YieldN/A
Average Volume (3M)493.98K
Price to Earnings (P/E)―
Beta (1Y)1.29
Revenue Growth54.96%
EPS Growth27.51%
CountryUS
Employees10,600
SectorHealthcare
Sector Strength74
IndustryBiotechnology
Share Statistics
EPS (TTM)-6.13
Shares Outstanding97,863,060
10 Day Avg. Volume785,256
30 Day Avg. Volume493,975
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)7.34
Price to Cash Flow (P/CF)93.10
P/FCF Ratio75.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$324.65Price Target Upside31.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
BeiGene Business Overview & Revenue Model
Company DescriptionBeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) is a global biotechnology company focused on developing innovative molecularly targeted and immuno-oncology drug candidates for the treatment of cancer. The company is committed to delivering affordable and accessible medicines to patients worldwide. BeiGene's core products include Brukinsa (zanubrutinib), a BTK inhibitor, and tislelizumab, an anti-PD-1 antibody, among other oncology therapies. The company operates primarily within the biopharmaceutical sector, with research and development facilities in China, the United States, and Australia.
How the Company Makes MoneyBeiGene generates revenue primarily through the sale of its commercialized pharmaceuticals, such as Brukinsa and tislelizumab, in various global markets. Additionally, the company earns income through collaborations and partnerships with other pharmaceutical companies, which may include licensing agreements, milestone payments, and royalties from marketed products developed in conjunction with partners. BeiGene also benefits from government grants and financial incentives related to its research and development activities. The company's strategy to expand its product portfolio and increase market penetration contributes significantly to its revenue growth.
BeiGene Financial Statement Overview
Summary
BeiGene shows strong revenue growth, reflecting its market expansion, but struggles with profitability and cash flow generation. The balance sheet is strong with low leverage, but cash flow challenges pose risks if external funding diminishes.Income Statement
BeiGene has shown significant revenue growth, from $308 million in 2020 to $3.81 billion in 2024, indicating strong top-line expansion. However, the company consistently reports negative EBIT and net income, reflecting ongoing challenges in achieving profitability. Gross profit margins have improved, but net profit margins remain negative, indicating operational inefficiencies or high R&D expenses typical in biotechnology.45
Neutral
Balance Sheet
The company maintains a strong equity base, with a debt-to-equity ratio consistently below 0.4, suggesting modest leverage. The equity ratio has decreased over the years, signaling a higher proportion of liabilities. The company's cash reserves remain robust, but declining trends in stockholders’ equity indicate potential financial pressures.55
Neutral
Cash Flow
Operating and free cash flows are negative, highlighting a reliance on external financing. The operating cash flow to net income ratio suggests operational challenges in generating cash from core business activities. With decreasing free cash flow, the company may face liquidity pressures without external funding.40
Negative
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 3.81B | 2.46B | 1.42B | 1.18B | 308.87M | Gross Profit |
| 3.22B | 2.08B | -511.06M | -447.86M | -1.06B | EBIT |
| -568.20M | -1.21B | -1.79B | -1.44B | -1.66B | EBITDA |
| -396.44M | -1.12B | -1.73B | -1.39B | -1.63B | Net Income Common Stockholders |
| -644.79M | -881.71M | -2.00B | -1.41B | -1.60B |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 2.63B | 3.17B | 4.54B | 6.62B | 4.66B | Total Assets |
| 5.92B | 5.81B | 6.38B | 8.65B | 5.60B | Total Debt |
| 1.08B | 930.18M | 891.13M | 694.64M | 561.96M | Net Debt |
| -1.55B | -2.24B | -2.98B | -3.68B | -819.99M | Total Liabilities |
| 2.59B | 2.27B | 2.00B | 2.40B | 1.73B | Stockholders Equity |
| 3.33B | 3.54B | 4.38B | 6.24B | 3.87B |
| Cash Flow | Free Cash Flow | |||
| -669.77M | -1.75B | -1.97B | -1.61B | -1.51B | Operating Cash Flow |
| -140.63M | -1.16B | -1.50B | -1.30B | -1.28B | Investing Cash Flow |
| -548.35M | 60.00M | 1.08B | 640.66M | -3.17B | Financing Cash Flow |
| 193.45M | 416.48M | -18.97M | 3.64B | 5.20B |
BeiGene Technical Analysis
Positive
247.07
Price Trends
220.11
Positive
210.85
Positive
194.42
Positive
Market Momentum
10.63
Positive
52.93
Neutral
32.20
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ONC, the sentiment is Positive. The current price of 247.07 is above the 20-day moving average (MA) of 245.74, above the 50-day MA of 220.11, and above the 200-day MA of 194.42, indicating a bullish trend. The MACD of 10.63 indicates Positive momentum. The RSI at 52.93 is Neutral, neither overbought nor oversold. The STOCH value of 32.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ONC.
BeiGene Risk Analysis
BeiGene disclosed 87 risk factors in its most recent earnings report. BeiGene reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
BeiGene Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $2.89B | ― | -5.71% | ― | -19.35% | -28.50% | |
59 Neutral | $3.86B | ― | -31.41% | ― | 49.59% | 24.92% | |
56 Neutral | $29.41B | ― | -18.77% | ― | 54.96% | 27.51% | |
49 Neutral | $7.05B | 0.34 | -55.09% | 2.46% | 25.27% | -3.43% | |
49 Neutral | $39.70M | ― | 60.38% | ― | 16.15% | 59.81% | |
45 Neutral | $69.39M | ― | -39.60% | ― | ― | ― | |
42 Neutral | $38.96M | ― | -270.20% | ― | 144.50% | -141.91% |
* Healthcare Sector Average
Performance Comparison
ONC
BeiGene
247.07
88.55
55.86%
BLUE
Bluebird Bio
4.00
-26.00
-86.67%
FGEN
FibroGen
0.37
-1.43
-79.44%
HCM
HUTCHMED
16.53
1.66
11.16%
ZLAB
Zai Lab
36.42
17.51
92.60%
IMAB
I-MAB
0.86
-0.99
-53.51%
BeiGene Earnings Call Summary
Earnings Call Date: Feb 27, 2025 | % Change Since: -4.61% | Next Earnings Date: May 1, 2025
Earnings Call Sentiment Positive
The earnings call highlighted strong financial performance and market leadership for BRUKINSA, along with robust R&D productivity. However, challenges remain in the competitive landscape and in achieving desired outcomes with fixed duration treatments. Overall, the positives significantly outweigh the negatives.Highlights
Record Revenue and Growth
BeiGene achieved $3.8 billion in revenue for the full year 2024, with $1.1 billion in Q4. This represented a 55% year-over-year revenue growth, with product revenues increasing by 73%.
BRUKINSA's Market Leadership
BRUKINSA became the BTKi class leader for new patient starts in the U.S., achieving $828 million in sales in Q4, representing a 100% growth compared to Q4 2023.
Strong Financial Guidance for 2025
BeiGene projected revenue for 2025 to be between $4.9 billion to $5.3 billion, with an expectation of full year GAAP operating breakeven and positive cash flow from operations.
R&D Productivity
Introduced 13 new molecular entities into the clinic in 2024, demonstrating strong R&D productivity and pipeline progress.
Lowlights
Challenges in Fixed Duration Treatment
Current fixed duration options like AMPLIFY did not meet expectations, showing lower MRD response rates and inferior PFS compared to continuous BRUKINSA therapy.
Competitive Market Dynamics
The CLL landscape remains competitive, with challenges posed by other treatment options such as venetoclax combinations.
Company Guidance
In BeiGene's Q4 and Full Year 2024 earnings call, the company provided strong financial and strategic guidance for 2025, projecting revenue between $4.9 billion to $5.3 billion, driven by continued global expansion and leadership in the BTK inhibitor market with BRUKINSA. The U.S. remains a significant market, contributing to the $3.8 billion total revenue in 2024, with BRUKINSA alone generating $828 million in Q4, marking a 100% year-over-year growth. For 2025, BeiGene expects stable net pricing in the U.S. and anticipates robust performance in Europe and rest of world markets, including Japan. The company aims to achieve full-year GAAP operating breakeven and positive cash flow from operations, emphasizing a disciplined investment approach to maintain a strong balance sheet while advancing their innovative pipeline. Key strategic focuses include solidifying leadership in the hematology franchise, advancing the pipeline of internally developed assets, and driving superior financial performance.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.